Abstract
Rationale In high-income countries less than half of asthma cases involve eosinophilic airways inflammation. Few studies have measured inflammatory asthma phenotypes in low- and-middle-income countries.
Objectives To assess asthma inflammatory phenotypes in Brazil, Ecuador, Uganda, New Zealand and the United Kingdom.
Methods We recruited 998 asthmatics and 356 non-asthmatics: 204/40 in Brazil, 176/67 in Ecuador, 235/132 in New Zealand, 207/50 in Uganda, and 176/67 in the United Kingdom. All centres studied children and adolescents (age-range 8-20 years), except the UK centre involved 26-27 year olds. Information was collected using questionnaires, clinical characterisation, blood, and induced sputum.
Measurements and main results 87% provided a sputum sample, ranging from 74% (Brazil) to 93% (United Kingdom); of these, 71% were countable. The proportion of asthmatics classified as eosinophilic asthma (EA) was 39% (95% confidence interval 35%-43%) overall: 35% in Brazil, 32% in Ecuador, 50% in New Zealand, 33% in Uganda, and 33% in the United Kingdom. The non-eosinophilic asthmatics (NEA) had similar severity/control to the eosinophilic asthmatics (EA). Of the 61% (95%CI 57%-65%) of cases with NEA, 50% showed no signs of inflammation (paucigranulocytic), with 11% having neutrophilic inflammation.
Conclusions This is the first time that sputum induction has been used to compare asthma inflammatory phenotypes in high-income countries and low-and-middle-income countries. Most cases were non-eosinophilic. This has major implications for asthma prevention and management in both of these contexts, and supports the need to recognise asthma as a heterogeneous condition, and to develop new prevention strategies and new therapies which target NEA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The World ASthma Phenotypes (WASP) collaboration is based on the AsthmaPhenotypes study which is funded by the European Research Council under the European Union Seventh Framework Programme (FP7/2007-2013) / ERC grant agreement no 668954. ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. Alison Elliott and Philip Cooper were funded by Wellcome Trust grant numbers 095778 and 088862, respectively.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
London School of Hygiene and Tropical Medicine Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* John Henderson was deceased in 2019, but played a major role in all aspects of the study design and data collection
Abstract has been revised to fit journal format and the spelling of one author's name has been corrected
Data Availability
Data is currently not available. We will consider requests for data sharing after the main findings have been published.
